1Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002; 288: 1758–1761.
2Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. Archives of Internal Medicine 1999; 159: 2177–2183.
3Meigs JB. Epidemiology of the insulin resistance syndrome. Current Diabetes Report 2003; 3: 73–79.
4Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541–1545.
5Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension?0. Hypertension 2004; 44: 12–19.
6Hall JE. The kidney, hypertension and obesity. Hypertension 2003; 41 (Part 2): 625–633.
7Hall JE, Henegar JR, Shek EW, Brands MW. Role of renin–angiotensin system in obesity hypertension. Circulation 1997; 96: I–33.
8Robles RG, Villa E, Santirso R, Martinez J, Ruilope LM, Cuesta C, et al. . Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. American Journal of Hypertension 1993; 6: 1009–1019.
9Reisen E, Weir M, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinoprin versus hydrochlorothiazide in obese hypertensive patients. Hypertension 1997; 30: 140–145.
10Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Hormone and Metabolic Research 2000; 32: 485–499.
11Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M. Angiotensinogen, angiotensin II and adipose tissue development. International Journal of Obesity Related Metabolic Disorder 2000; 24: S33–S35.
12Rotimi C, Cooper R, Ogunbiyi O, Morrison L, Ladipo M, Tewksbury D, et al. . Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Circulation 1997; 95: 2348–2350.
13Pratt JH, Ambrosius WT, Tewksbury DA, Wagner MA, Zhou L, Hanna MP. Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people. Hypertension 1998; 32: 875–879.
14Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. . Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB Journal 2001; 15: 2727–2729.
15Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al. . Blockade of the renin–angiotensin system decreases adipocyte size with improvement in insulin sensitivity. Journal of Hypertension 2004; 22: 1977–1982.
16Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, et al. . Deletion of the angiotensin type 2 receptor (AT2R) reduces adipocyte cell size and protects from diet induced obesity and insulin resistance. Diabetes 2005; 54: 991–999.
17Ailhaud G. Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. Annals of New York of Academic Science 1999; 892: 127–133.
18Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004; 145: 169–174.
19Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communication 1999; 257: 79–83.
20Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. . Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767–2770.
21Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. . Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.
22Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. . Weight loss and the renin–angiotensin–aldosterone system. Hypertension 2005; 45: 356–362.
23Rahmouni K, Correia MLG, Haynes WG, Mark AL. Obesity-associated hypertension. New insights into mechanisms. Hypertension 2005; 45: 9–14.
24Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43: 518–524.
25Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. . Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academic Science USA 2003; 100: 14211–14216.
26Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358–363.
27de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41–47.
28Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286–288.
29Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
30Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. . Metabolic syndrome and target organ damage in untreated essential hypertensives. Journal of Hypertension 2004; 22: 1991–1998.
31Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. . The metabolic syndrome and chronic kidney disease in US adults. Annals of Internal Medicine 2004; 140: 167–174.
32Safar ME, Thomas F, Blacher J, Nzietchueng R, Bureau JM, Pannier B, et al. . Metabolic syndrome and age-related progression of aortic stiffness. Journal of Amercian College of Cardiology 2006; 47: 72–75.
33Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.
34Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care 2004; 27: 2444–2449.
35Banegas JR, Ruilope LM. Epidemic of metabolic diseases. A warning call. Medicina Clinica (Barcelona) 2003; 120: 99–100.
36Segura J, Campo C, Roldan C, Christiansen H, Vigil L, García-Robles R, et al. . Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. Journal of American Society of Nephrology 2004; 15 (Suppl. 1): S37–S42.
37Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. . Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27: 2689–2694.
38Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
39Grundy SM, Hansen B, JrSmith SC, Cleeman JI, Kahn RA, American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551–556.
40Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
41Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of American Medical Association 2002; 288: 2709–2716.
42Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. ; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004; 364: 937–952.
43Porier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. . Obesity and cardiovascular disease. Pathophysiology, evaluation and effect of weight loss. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26: 968–976.
44Schiel R, Beltschikow W, Kramer G, Stein G. Overweight, obesity and elevated blood pressure in children and adolescents. European Journal of Medical Research 2006; 11: 97–101.
45Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects. The Bogalusa Heart Study. Hypertension 2006; 48: 33–39.
46Bacha F, Saad R, Gungor N, Arslanian SA. Are obesity-related metabolic risk factors modulated by the degree of insulin resistance in adolescents. Diabetes Care 2006; 29: 1599–1604.
47Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al. ; on behalf of the CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43: 1338–1344.
48Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, JrIzzo JL, et al. ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2571.
49Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011–1053.
50Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? Journal of Hypertension 2001; 19: 667–674.
51Segura J, Campo C, Ruilope LM, Rodicio JL. Do we need to target ‘prediabetic’ hypertensive patients? Journal of Hypertension 2005; 23: 2119–2125.
52 Segura J, Ruilope LM. Antihypertensive therapy in patients with metabolic syndrome. Current Opinion in Nephrology and Hypertension 2006; 15: 493–497.